Furthermore, EX103 demonstrates promising efficacy in heavily pretreated patients with R/R B-NHL, including some who have previously failed CAR-T treatment. The safety and efficacy of EX103 will be further evaluated in an ongoing clinical study.
The preliminary Disease Control Rate (DCR) is 84.6% (11/13). Conclusions The preliminary data show favorable safety and remarkable antitumor activity, even at low doses, in heavily pretreated patients with R/R B-NHL, including those who failed prior CAR-T therapy.